A pharmacological inhibitor (KN-93) of the calcium/calmodulin-dependent kinase (CaMKII)60 and transgenic expression of CaMKII peptide inhibitor in VSMC have been reported to attenuate hypertension after angiotensin II infusion by controlling baroreceptor function61. This evidence concerns the gene CAMK2G and Hypertension.